Conservation of Aging and Cancer Epigenetic Signatures across Human and Mouse.


Journal

Molecular biology and evolution
ISSN: 1537-1719
Titre abrégé: Mol Biol Evol
Pays: United States
ID NLM: 8501455

Informations de publication

Date de publication:
29 07 2021
Historique:
pubmed: 20 4 2021
medline: 21 9 2021
entrez: 19 4 2021
Statut: ppublish

Résumé

Aging and cancer are two interrelated processes, with aging being a major risk factor for the development of cancer. Parallel epigenetic alterations have been described for both, although differences, especially within the DNA hypomethylation scenario, have also been recently reported. Although many of these observations arise from the use of mouse models, there is a lack of systematic comparisons of human and mouse epigenetic patterns in the context of disease. However, such comparisons are significant as they allow to establish the extent to which some of the observed similarities or differences arise from pre-existing species-specific epigenetic traits. Here, we have used reduced representation bisulfite sequencing to profile the brain methylomes of young and old, tumoral and nontumoral brain samples from human and mouse. We first characterized the baseline epigenomic patterns of the species and subsequently focused on the DNA methylation alterations associated with cancer and aging. Next, we described the functional genomic and epigenomic context associated with the alterations, and finally, we integrated our data to study interspecies DNA methylation levels at orthologous CpG sites. Globally, we found considerable differences between the characteristics of DNA methylation alterations in cancer and aging in both species. Moreover, we describe robust evidence for the conservation of the specific cancer and aging epigenomic signatures in human and mouse. Our observations point toward the preservation of the functional consequences of these alterations at multiple levels of genomic regulation. Finally, our analyses reveal a role for the genomic context in explaining disease- and species-specific epigenetic traits.

Identifiants

pubmed: 33871658
pii: 6237917
doi: 10.1093/molbev/msab112
pmc: PMC8321527
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3415-3435

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution.

Références

PLoS Genet. 2015 Dec 10;11(12):e1005661
pubmed: 26658498
Brief Funct Genomics. 2013 May;12(3):279-87
pubmed: 23426092
Aging Cell. 2018 Jun;17(3):e12744
pubmed: 29504244
Genome Biol. 2012 Oct 03;13(10):R87
pubmed: 23034086
Nat Methods. 2018 Jul;15(7):475-476
pubmed: 29967506
PLoS Genet. 2009 Jan;5(1):e1000325
pubmed: 19119423
Genome Biol. 2012 Aug 31;13(8):R77
pubmed: 22937822
PLoS Genet. 2015 Aug 04;11(8):e1005442
pubmed: 26241857
Nat Rev Mol Cell Biol. 2015 Sep;16(9):519-32
pubmed: 26296162
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):
pubmed: 27194046
Transl Psychiatry. 2019 Jan 29;9(1):39
pubmed: 30696804
Genome Biol. 2017 Mar 28;18(1):57
pubmed: 28351423
Sci Rep. 2015 Nov 25;5:16923
pubmed: 26603754
Genome Res. 2006 May;16(5):669-77
pubmed: 16606702
Nucleic Acids Res. 2015 Sep 30;43(17):8204-14
pubmed: 26170231
Nat Commun. 2017 Sep 14;8(1):539
pubmed: 28912502
Epigenomics. 2010 Apr;2(2):245-69
pubmed: 22121873
Nature. 2020 Jul;583(7818):744-751
pubmed: 32728240
Nat Rev Cancer. 2017 Jun;17(6):337-351
pubmed: 28450705
Brain Res. 2019 Feb 15;1705:48-65
pubmed: 29544733
Cell. 2016 Sep 22;167(1):233-247.e17
pubmed: 27662091
Genome Biol. 2017 Mar 28;18(1):58
pubmed: 28351383
Nat Rev Mol Cell Biol. 2019 Oct;20(10):590-607
pubmed: 31399642
Genome Res. 2005 Aug;15(8):1034-50
pubmed: 16024819
Nat Biotechnol. 2010 Oct;28(10):1106-14
pubmed: 20852634
Brain Res. 2019 Feb 15;1705:1-14
pubmed: 29522720
Curr Opin Genet Dev. 1996 Dec;6(6):743-8
pubmed: 8994846
Science. 2013 Aug 9;341(6146):1237905
pubmed: 23828890
Bioinformatics. 2017 Aug 1;33(15):2381-2383
pubmed: 28369316
Bioinformatics. 2016 Feb 15;32(4):587-9
pubmed: 26508757
PLoS One. 2011 Feb 15;6(2):e17121
pubmed: 21347206
Genome Biol. 2017 Mar 28;18(1):56
pubmed: 28351387
Epigenetics. 2018;13(7):721-741
pubmed: 30009687
BMC Genomics. 2017 Sep 12;18(1):724
pubmed: 28899353
Cancer Res. 2020 Feb 1;80(3):367-374
pubmed: 31694907
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D493-6
pubmed: 14681465
J Neurosci. 2013 Jul 31;33(31):12586-98
pubmed: 23904596
Life Sci. 2016 May 1;152:244-8
pubmed: 26596563
J Cell Sci. 2003 Oct 15;116(Pt 20):4181-90
pubmed: 12972506
Nat Rev Mol Cell Biol. 2019 Oct;20(10):573-589
pubmed: 31270442
Nat Cell Biol. 2001 Nov;3(11):983-91
pubmed: 11715019
Microbiol Mol Biol Rev. 2016 Jun 01;80(3):545-63
pubmed: 27250769
Pharmaceuticals (Basel). 2017 Feb 12;10(1):
pubmed: 28208677
Genome Res. 2010 Jul;20(7):972-80
pubmed: 20488932
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Nat Biotechnol. 2010 Aug;28(8):817-25
pubmed: 20657582
Br J Cancer. 2020 May;122(11):1580-1589
pubmed: 32291392
Hum Mol Genet. 2016 Jan 15;25(2):223-32
pubmed: 26566671
Genome Res. 2014 Apr;24(4):580-91
pubmed: 24414704
Elife. 2013 Feb 26;2:e00348
pubmed: 23467541
Cell Rep. 2014 Jul 24;8(2):487-500
pubmed: 25043184
Cell. 2015 Sep 24;163(1):39-53
pubmed: 26406370
J Cell Sci. 2012 Nov 15;125(Pt 22):5502-13
pubmed: 22956546
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cell Stem Cell. 2014 May 1;14(5):673-88
pubmed: 24792119
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Bioinformatics. 2018 Sep 15;34(18):3208-3210
pubmed: 29718111
Nucleic Acids Res. 2018 Aug 21;46(14):7022-7039
pubmed: 29893918
Nat Methods. 2012 Feb 28;9(3):215-6
pubmed: 22373907
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Mech Ageing Dev. 2019 Jan;177:30-36
pubmed: 29574045
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D590-8
pubmed: 16381938
Cold Spring Harb Perspect Biol. 2013 Nov 01;5(11):a017939
pubmed: 24186070
Anticancer Res. 2019 Jan;39(1):99-106
pubmed: 30591445
Aging (Albany NY). 2019 Nov 13;11(21):9794-9810
pubmed: 31724536
Epigenetics Chromatin. 2019 Oct 8;12(1):58
pubmed: 31594536
Hum Reprod Update. 2018 Sep 1;24(5):556-576
pubmed: 29992283
Cell. 2016 Aug 11;166(4):822-839
pubmed: 27518561
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
Bioinformatics. 2011 Jun 1;27(11):1571-2
pubmed: 21493656
Br J Cancer. 2013 Jan 15;108(1):64-71
pubmed: 23321511
Mol Biol Evol. 2016 Nov;33(11):2947-2959
pubmed: 27563052
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Front Genet. 2019 Oct 01;10:906
pubmed: 31632439
Nat Rev Genet. 2011 Feb;12(2):123-35
pubmed: 21221116
Mol Biol Evol. 2008 Aug;25(8):1602-8
pubmed: 18469331
Nat Commun. 2019 Sep 25;10(1):4361
pubmed: 31554804
Genome Res. 2015 Jan;25(1):27-40
pubmed: 25271306
Aging Cell. 2017 Dec;16(6):1342-1352
pubmed: 28948711
Aging Dis. 2017 Oct 1;8(5):628-642
pubmed: 28966806

Auteurs

Raúl F Pérez (RF)

Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), University of Oviedo, Oviedo, Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain.
Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain.
Department of Organisms and Systems Biology (B.O.S.), University of Oviedo, Oviedo, Spain.
Rare Diseases CIBER (CIBERER) of the Carlos III Health Institute (ISCIII), Madrid, Spain.

Juan Ramón Tejedor (JR)

Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), University of Oviedo, Oviedo, Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain.
Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain.
Department of Organisms and Systems Biology (B.O.S.), University of Oviedo, Oviedo, Spain.
Rare Diseases CIBER (CIBERER) of the Carlos III Health Institute (ISCIII), Madrid, Spain.

Pablo Santamarina-Ojeda (P)

Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), University of Oviedo, Oviedo, Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain.
Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain.
Department of Organisms and Systems Biology (B.O.S.), University of Oviedo, Oviedo, Spain.
Rare Diseases CIBER (CIBERER) of the Carlos III Health Institute (ISCIII), Madrid, Spain.

Virginia López Martínez (VL)

Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), University of Oviedo, Oviedo, Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain.
Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain.
Department of Organisms and Systems Biology (B.O.S.), University of Oviedo, Oviedo, Spain.
Rare Diseases CIBER (CIBERER) of the Carlos III Health Institute (ISCIII), Madrid, Spain.

Rocío G Urdinguio (RG)

Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), University of Oviedo, Oviedo, Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain.
Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain.
Department of Organisms and Systems Biology (B.O.S.), University of Oviedo, Oviedo, Spain.
Rare Diseases CIBER (CIBERER) of the Carlos III Health Institute (ISCIII), Madrid, Spain.

Lucía Villamañán (L)

Unitat de Bioquímica de Biociències, Departament de Bioquímica i Biologia Molecular, Edifici Cs, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.

Ana Paula Candiota (AP)

Unitat de Bioquímica de Biociències, Departament de Bioquímica i Biologia Molecular, Edifici Cs, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.

N Mí Vidal Sarró (NMV)

Servicio Anatomía Patológica, Hospital Universitari de Bellvitge-IDIBELL, Hospitalet de Llobregat, Spain.

Marta Barradas (M)

Metabolic Syndrome Group-BIOPROMET, Madrid Institute for Advanced Studies-IMDEA Food, CEI UAM+CSIC, Madrid, Spain.

Pablo Jose Fernandez-Marcos (PJ)

Metabolic Syndrome Group-BIOPROMET, Madrid Institute for Advanced Studies-IMDEA Food, CEI UAM+CSIC, Madrid, Spain.

Manuel Serrano (M)

Tumour Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Cellular Plasticity and Disease Group, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.

Agusín F Fernández (AF)

Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), University of Oviedo, Oviedo, Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain.
Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain.
Department of Organisms and Systems Biology (B.O.S.), University of Oviedo, Oviedo, Spain.
Rare Diseases CIBER (CIBERER) of the Carlos III Health Institute (ISCIII), Madrid, Spain.

Mario F Fraga (MF)

Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), University of Oviedo, Oviedo, Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain.
Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain.
Department of Organisms and Systems Biology (B.O.S.), University of Oviedo, Oviedo, Spain.
Rare Diseases CIBER (CIBERER) of the Carlos III Health Institute (ISCIII), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH